Fulcrum Therapeutics, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Jun 2018 | — | — | $8.0M |
| Sep 2018 | — | — | $82.8M |
| Dec 2018 | $9.8M | $85.8M | $72.8M |
| Mar 2019 | — | — | $62.5M |
| Jun 2019 | $11.7M | $65.2M | $49.6M |
| Sep 2019 | $13.8M | $116.0M | $101.6M |
| Dec 2019 | $23.3M | $110.4M | $96.7M |
| Mar 2020 | $24.2M | $94.9M | $25.4M |
| Jun 2020 | $22.7M | $144.9M | $75.7M |
| Sep 2020 | $37.2M | $142.2M | $85.2M |
| Dec 2020 | $34.4M | $129.6M | $57.1M |
| Mar 2021 | $28.7M | $156.5M | $100.7M |
| Jun 2021 | $27.0M | $137.9M | $56.8M |
| Sep 2021 | $24.9M | $255.5M | $65.5M |
| Dec 2021 | $23.5M | $235.0M | $35.4M |
| Mar 2022 | $31.1M | $220.2M | $33.3M |
| Jun 2022 | $34.5M | $195.2M | $40.2M |
| Sep 2022 | $26.4M | $247.8M | $90.9M |
| Dec 2022 | $27.7M | $226.7M | $35.1M |
| Mar 2023 | $24.9M | $321.1M | $34.7M |
| Jun 2023 | $24.9M | $300.3M | $34.0M |
| Sep 2023 | $23.4M | $278.9M | $30.1M |
| Dec 2023 | $22.5M | $257.7M | $25.6M |
| Mar 2024 | $19.0M | $232.6M | $39.9M |
| Jun 2024 | $20.5M | $294.3M | $86.7M |
| Sep 2024 | $21.7M | $279.0M | $72.6M |
| Dec 2024 | $17.7M | $260.7M | $58.2M |
| Mar 2025 | $14.2M | $242.6M | $42.2M |
| Jun 2025 | $14.5M | $228.8M | $42.6M |
| Sep 2025 | $16.5M | $214.9M | $47.1M |
| Dec 2025 | $17.3M | $366.3M | $197.5M |
| Mar 2026 | $13.5M | $346.8M | $50.3M |
| Jun 2026 | $13.3M | $324.0M | $48.5M |